We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Three Commercial Tests for Lyme Borreliosis Evaluated

By LabMedica International staff writers
Posted on 15 Aug 2017
Print article
Image: The automated ELISA instrument (Photo courtesy of Dynex Technologies).
Image: The automated ELISA instrument (Photo courtesy of Dynex Technologies).
The recommended approach for the diagnosis of Lyme borreliosis consists of screening for Borrelia-specific serum antibodies with an enzyme-linked immunosorbent assay (ELISA), followed by immunoblot confirmation of equivocal or positive ELISA results.

The reliability of the serodiagnosis of Lyme borreliosis is influenced by various factors, including the manifestation and the duration of disease, the natural clearance of infection, antibiotic treatment, (age-specific) seroprevalence and the test characteristics, such as the antigens used.

A team of scientists led by those at the Diakonessenhuis Hospital (Utrecht, The Netherlands) investigated the diagnostic characteristics of two enzyme-linked immunosorbent assays (ELISAs) and an immunoblot for the detection of Borrelia-specific serum antibodies using different test strategies in individuals with and without antibiotic treatment for Lyme borreliosis. The retrospective study included 174 healthy individuals, of whom 27 (15.5%) were treated for Lyme borreliosis in the past, 36 patients were treated for Lyme neuroborreliosis and 27 patients had active Lyme neuroborreliosis For inclusion in the study, intrathecal IgM/IgG was determined by the second-generation IDEIA Lyme Neuroborreliosis test.

Serum samples of all study subjects were tested in two ELISAs and one immunoblot. All tests were performed using an automated Dynex DS2 ELISA instrument. The two ELISAs used were the C6 ELISA, which is based on a synthetic C6 peptide, which is derived from a highly immunogenic part (invariable region 6) of the VlsE lipoprotein and the SERION ELISA classic Borrelia IgM and IgG tests.

The team reported that all the active Lyme neuroborreliosis patients were reactive in both ELISAs (100% sensitivity); less reactivity was seen in the other three groups (range 17.7% to 69.4%). The concordance between the ELISA results was high in active Lyme neuroborreliosis patients (26/27; 96.3%) and healthy individuals (131/147; 89.1%), but lower in treated healthy individuals (18/27; 66.7%) and treated Lyme neuroborreliosis patients (18/36; 50.0%). They also showed that antibiotic treatment against Lyme borreliosis was strongly associated with discordant ELISA and test strategy results. This suggests that antibiotic treatment influences the pace at which the various antibodies directed to the different antigens used in both ELISAs wane.

The authors concluded that among treated neuroborreliosis patients, the SERION ELISA stayed positive for a longer period after infection compared to the C6 ELISA and this should be taken into consideration when requesting and/or interpreting Lyme serology. The study was published on July 26, 2017, in the European Journal of Clinical Microbiology & Infectious Diseases.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.